Toronto, Ontario–(Newsfile Corp. – February 3, 2022) – Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K70) (“Silo Wellness” or the “Company“), a leading global psychedelics company, is pleased to announce that it has entered into a subscription agreement (the “Subscription Agreement“) with respect to a strategic investment (the... Read more
Silo Wellness Inc signs distribution deal with Flawless CBD for functional mushroom products
February 2, 2022
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any... Read more
Clearmind Medicine Partners with Dr. Gabor Maté to Discuss Alcohol Use Disorder and Trauma in a Special Virtual Event on February 3
January 28, 2022
Ryan Allway January 28th, 2022 Psychedelics A renowned speaker, and bestselling author, Dr. Gabor Maté is highly sought after for his expertise on a range of topics including addiction, stress and childhood development TORONTO, Jan. 28, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF) (“Clearmind” or... Read more
Ryan Allway January 28th, 2022 Psychedelics, Top Story Psychedelics have shown tremendous promise in treating depression, anxiety, post-traumatic stress disorder, and a range of other mental health conditions. In particular, assisted psychotherapy combines psychedelic substances with talk therapy to facilitate breakthroughs and help patients that don’t see relief through... Read more
SciSparc Presents New Leadership Lineup
January 27, 2022
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any... Read more
Revitalist Provides Summary of 2021, Reporting Patient Visits of 5,000, a 128% Increase From 2020
January 21, 2022
Ryan Allway January 21st, 2022 Psychedelics, Top News REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist” or the “Company”) (CSE: CALM) (OTC: RVLWF) (FSE: 4DO) is pleased to recap the milestones the Company reached in the calendar year 2021. The Company has significantly scaled its operations during 2021, ending the year... Read more
BetterLife Receives FDA Response On Its Pre-IND Application For Major Depressive Disorder (MDD) Treatment With BETR-001
January 20, 2022
Ryan Allway January 20th, 2022 Psychedelics VANCOUVER, British Columbia, Jan. 20, 2022 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of 2nd-generation non-hallucinogenic psychedelic analogs for the treatment of neuropsychological disorders, is pleased to... Read more
FSD Pharma Announces Launch of New Corporate Website
January 20, 2022
Ryan Allway January 20th, 2022 News, Psychedelics New Website Shares FSD’s Unique Drug Pipeline and Vision to Improve the Quality of Life for Patients Suffering from Brain & Inflammatory Disorders TORONTO, January 20, 2022–(BUSINESS WIRE)–FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company“), a... Read more
Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase 1 DMT Human Stroke Study
January 19, 2022
Ryan Allway January 19th, 2022 Psychedelics VANCOUVER, British Columbia, Jan. 19, 2022 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has filed a combined Clinical Trials of Investigational Medicinal... Read more
BetterLife Obtains Positive In Vivo Oral Bioavailability, Food Effect and Pharmacokinetics Data for BETR-001
January 18, 2022
Ryan Allway January 18th, 2022 Psychedelics VANCOUVER, British Columbia, Jan. 18, 2022 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of 2nd-generation non-hallucinogenic psychedelic analogs for the treatment of neuropsychological disorders, is pleased to... Read more
